jrnl1941

Publication Venue For

  • Patient-reported outcome measures for life participation in kidney transplantation: A systematic review.  19:2306-2317. 2019
  • The impact of donor and recipient common clinical and genetic variation on estimated glomerular filtration rate in a European renal transplant population.  19:2262-2273. 2019
  • Variation in use of procurement biopsies and its implications for discard of deceased donor kidneys recovered for transplantation.  19:2241-2251. 2019
  • Time for reform in transplant program–specific reporting: AST/ASTS transplant metrics taskforce.  19:1888-1895. 2019
  • Optimal timing of hepatitis C treatment among HIV/HCV coinfected ESRD patients: Pre- vs posttransplant.  19:1806-1819. 2019
  • Long-term follow-up of the DeKAF cross-sectional cohort study.  19:1432-1443. 2019
  • Repeat kidney transplant recipients with active rejection have elevated donor-derived cell-free DNA.  19:1597-1598. 2019
  • Phase I study of single-dose pharmacokinetics and pharmacodynamics of belatacept in adolescent kidney transplant recipients.  19:1218-1223. 2019
  • The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients: The Transplant Therapeutics Consortium's position statement.  19:625-632. 2019
  • Allograft and patient survival after sequential HSCT and kidney transplantation from the same donor—A multicenter analysis.  19:475-487. 2019
  • Banff survey on antibody-mediated rejection clinical practices in kidney transplantation: Diagnostic misinterpretation has potential therapeutic implications.  19:123-131. 2019
  • Get on with it!—A novel allocation strategy to reduce kidney discards 2019
  • Tacrolimus troughs and genetic determinants of metabolism in kidney transplant recipients: A comparison of four ancestry groups 2019
  • The Banff schema for antibody-mediated rejection: Lost in translation?.  19:9-10. 2019
  • Use of ex vivo normothermic machine perfusion after normothermic regional perfusion to salvage a poorly perfused DCD kidney 2019
  • WNT pathway signaling is associated with microvascular injury and predicts kidney transplant failure 2019
  • What's hot, what's new: Report from the American Transplant Congress 2018.  18:2857-2868. 2018
  • Can you hear me now? Patient preferences for evaluating kidney transplant centers.  18:2624. 2018
  • Current opinions in organ allocation.  18:2625-2634. 2018
  • Organs from deceased donors with false-positive HIV screening tests: An unexpected benefit of the HOPE act.  18:2579-2586. 2018
  • Population level outcomes and cost-effectiveness of hepatitis C treatment pre- vs postkidney transplantation.  18:2483-2495. 2018
  • Meeting report of the STAR—Sensitization in Transplantation Assessment of Risk: Naïve Abdominal Transplant Organ subgroup focus on kidney transplantation.  18:2120-2134. 2018
  • Response to “It is time to revise the kidney allocation system to restore the pediatric advantage”.  18:2367. 2018
  • Subclinical inflammation phenotypes and long-term outcomes after pediatric kidney transplantation.  18:2189-2199. 2018
  • Impact of the new kidney allocation system A2/A2B → B policy on access to transplantation among minority candidates.  18:1947-1953. 2018
  • Decreasing deceased donor transplant rates among children (≤6 years) under the new kidney allocation system.  18:1690-1698. 2018
  • Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report.  18:1604-1614. 2018
  • Expanding clarity or confusion? Volatility of the 5-tier ratings assessing quality of transplant centers in the United States.  18:1494-1501. 2018
  • Response to: Regarding “HIV protease inhibitors and mortality following kidney transplantation”.  18:1571. 2018
  • Human polyomavirus-7–associated eruption successfully treated with acitretin.  18:1278-1284. 2018
  • Late graft failure after kidney transplantation as the consequence of late versus early events.  18:1158-1167. 2018
  • Assessing emergency department utilization in the era of population health.  18:777-778. 2018
  • Hospital readmissions following HLA-incompatible live donor kidney transplantation: A multi-center study.  18:650-658. 2018
  • The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.  18:293-307. 2018
  • Urologic malignancies in kidney transplantation.  18:13-22. 2018
  • Impact of Protease Inhibitor–Based Anti-Retroviral Therapy on Outcomes for HIV+ Kidney Transplant Recipients.  17:3114-3122. 2017
  • The Incremental Cost of Incompatible Living Donor Kidney Transplantation: A National Cohort Analysis.  17:3123-3130. 2017
  • Real Time Central Assessment of Kidney Transplant Indication Biopsies by Microarrays: The INTERCOMEX Study.  17:2851-2862. 2017
  • B Cell Receptor Genes Associated With Tolerance Identify a Cohort of Immunosuppressed Patients With Improved Renal Allograft Graft Function.  17:2627-2639. 2017
  • Lessons Learned: Early Termination of a Randomized Trial of Calcineurin Inhibitor and Corticosteroid Avoidance Using Belatacept.  17:2712-2719. 2017
  • PROviding Better ACcess To ORgans: A comprehensive overview of organ-access initiatives from the ASTS PROACTOR Task Force.  17:2546-2558. 2017
  • Urinary Markers of Fibrosis and Risk of Cardiovascular Events and Death in Kidney Transplant Recipients: The FAVORIT Trial.  17:2640-2649. 2017
  • Risk of End-Stage Renal Disease in HIV-Positive Potential Live Kidney Donors.  17:1823-1832. 2017
  • Effect of Replacing Race With Apolipoprotein L1 Genotype in Calculation of Kidney Donor Risk Index.  17:1540-1548. 2017
  • Renal Allograft Survival in Nonhuman Primates Infused With Donor Antigen-Pulsed Autologous Regulatory Dendritic Cells.  17:1476-1489. 2017
  • Selective Targeting of High-Affinity LFA-1 Does Not Augment Costimulation Blockade in a Nonhuman Primate Renal Transplantation Model.  17:1193-1203. 2017
  • Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection.  17:931-943. 2017
  • Ureteral Obstruction and New Groin Pain in a Kidney Transplant Recipient.  17:1139-1141. 2017
  • The White House Organ Summit.  17:576. 2017
  • Increased Mortality and Graft Loss With Kidney Retransplantation Among Human Immunodeficiency Virus (HIV)–Infected Recipients.  17:173-179. 2017
  • The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology.  17:28-41. 2017
  • Plasma-Derived C1 Esterase Inhibitor for Acute Antibody-Mediated Rejection Following Kidney Transplantation: Results of a Randomized Double-Blind Placebo-Controlled Pilot Study.  16:3468-3478. 2016
  • Splenic irradiation for the treatment of severe antibody-mediated rejection.  16:3041-3045. 2016
  • Transplantation of the heart after circulatory death.  16:3063. 2016
  • Anti–Blood Group Antibodies in Intravenous Immunoglobulin May Complicate Interpretation of Antibody Titers in ABO-Incompatible Transplantation.  16:2483-2486. 2016
  • Identification of Optimal Donor–Recipient Combinations Among Human Immunodeficiency Virus (HIV)–Positive Kidney Transplant Recipients.  16:2377-2383. 2016
  • Induction Immunosuppression and Clinical Outcomes in Kidney Transplant Recipients Infected With Human Immunodeficiency Virus.  16:2368-2376. 2016
  • Proteomic Characterization Reveals That MMP-3 Correlates With Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Cell and Lung Transplantation.  16:2342-2351. 2016
  • Regulatory T Cell Infusion Can Enhance Memory T Cell and Alloantibody Responses in Lymphodepleted Nonhuman Primate Heart Allograft Recipients.  16:1999-2015. 2016
  • Anti-Leukocyte Function-Associated Antigen 1 Therapy in a Nonhuman Primate Renal Transplant Model of Costimulation Blockade-Resistant Rejection.  16:1456-1464. 2016
  • Economic Impacts of ABO-Incompatible Live Donor Kidney Transplantation: A National Study of Medicare-Insured Recipients.  16:1465-1473. 2016
  • Developing New Immunosuppression for the Next Generation of Transplant Recipients: The Path Forward.  16:1094-1101. 2016
  • Protein Quantitative Trait Loci Analysis Identifies Genetic Variation in the Innate Immune Regulator TOLLIP in Post-Lung Transplant Primary Graft Dysfunction Risk.  16:833-840. 2016
  • Control of Immune Response to Allogeneic Embryonic Stem Cells by CD3 Antibody-Mediated Operational Tolerance Induction.  16:454-467. 2016
  • Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles.  16:574-582. 2016
  • Persistence of Indirect but Not Direct T Cell Xenoresponses in Baboon Recipients of Pig Cell and Organ Transplants.  16:1917-1922. 2016
  • Presentation and outcomes of C4d-negative antibody-mediated rejection after kidney transplantation.  16:213-220. 2016
  • Where the Sun shines: Industry's payments to transplant surgeons.  16:292-300. 2016
  • First report on the OPTN national variance: Allocation of A2/A2B deceased donor kidneys to blood group B increases minority transplantation.  15:3134-3142. 2015
  • Longitudinal Studies of a B Cell-Derived Signature of Tolerance in Renal Transplant Recipients.  15:2908-2920. 2015
  • Center-Level Experience and Kidney Transplant Outcomes in HIV-Infected Recipients.  15:2096-2104. 2015
  • Sequential monitoring and stability of Ex vivo-expanded autologous and nonautologous regulatory t cells following infusion in nonhuman primates.  15:1253-1266. 2015
  • A pilot trial targeting the icos-icos-l pathway in nonhuman primate kidney transplantation.  15:984-992. 2015
  • Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure.  15:1615-1622. 2015
  • Center-Level Experience and Kidney Transplant Outcomes in HIV-Infected Recipients 2015
  • Frailty and mortality in kidney transplant recipients.  15:149-154. 2015
  • Hospital-onset Clostridium difficile infection among solid organ transplant recipients.  15:2970-2977. 2015
  • Loss of pediatric kidney grafts during the "high-risk age window": Insights from pediatric liver and simultaneous liver-kidney recipients.  15:445-452. 2015
  • Objective Estimates Improve Risk Stratification for Primary Graft Dysfunction after Lung Transplantation.  15:2188-2196. 2015
  • Quantifying renal allograft loss following early antibody-mediated rejection.  15:489-498. 2015
  • The impact of proposed changes in liver allocation policy on cold ischemia times and organ transportation costs.  15:541-546. 2015
  • Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation.  14:459-465. 2014
  • Kidneys at higher risk of discard: Expanding the role of dual kidney transplantation.  14:404-415. 2014
  • Preoperative plasma club (Clara) cell secretory protein levels are associated with primary graft dysfunction after lung transplantation.  14:446-452. 2014
  • To transplant a kidney with the heart or not - That is the real question.  14:253-254. 2014
  • A randomized, double-blind, placebo-controlled, multicenter study of rabbit ATG in the prophylaxis of acute rejection in lung transplantation.  14:1191-1198. 2014
  • Emotional well-being of living kidney donors: Findings from the RELIVE study.  14:2535-2544. 2014
  • Epidemiology of invasive mold infections in lung transplant recipients.  14:1328-1333. 2014
  • Hemorrhagic shock one month following uncomplicated liver transplantation.  14:1461-1463. 2014
  • Impact of the lung allocation score on survival beyond 1 year.  14:2288-2294. 2014
  • Pig-to-monkey islet xenotransplantation using multi-transgenic pigs.  14:2275-2287. 2014
  • Quantifying the risk of incompatible kidney transplantation: A multicenter study.  14:1573-1580. 2014
  • Role of left ventricular assist devices in assessment of patients for combined heart-kidney transplantation.  14:1946-1947. 2014
  • The microbiota, the immune system and the allograft.  14:1236-1248. 2014
  • Transmission of Balamuthia mandrillaris through solid organ transplantation: Utility of organ recipient serology to guide clinical management.  14:1417-1424. 2014
  • Inhibition of αvβ6 promotes acute renal allograft rejection in nonhuman primates.  13:3085-3093. 2013
  • Necroptosis in solid organ transplantation: A missing link to immune activation?.  13:2785-2786. 2013
  • Ex vivo-expanded cynomolgus macaque regulatory T cells are resistant to Alemtuzumab-mediated cytotoxicity.  13:2169-2178. 2013
  • Regulatory dendritic cell infusion prolongs kidney allograft survival in nonhuman primates.  13:1989-2005. 2013
  • Multicenter evaluation of a standardized protocol for noninvasive gene expression profiling.  13:1891-1897. 2013
  • What liver transplant outcomes can be expected in the uninsured who become insured via the affordable care act?.  13:1533-1540. 2013
  • Progressive multifocal leukoencephalopathy in a heart transplant recipient following rituximab therapy for antibody-mediated rejection.  13:1075-1079. 2013
  • The aggressive phenotype revisited: Utilization of higher-risk liver allografts.  13:936-942. 2013
  • Cryptococcosis in solid organ transplantation.  13:242-249. 2013
  • Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion.  13:320-328. 2013
  • Demographic, metabolic, and blood pressure characteristics of living kidney donors spanning five decades.  13:390-398. 2013
  • A 16-year multi-institutional study of the role of age and EBV status on PTLD incidence among pediatric heart transplant recipients.  12:3061-3068. 2012
  • Erratum: A realistic proposal-incentives may increase donation - We need trials now! (American Journal of Transplantation (2012) 12 (1957-1958) DOI:10.1111/j.1600-6143.2012.04117.x).  12:2261. 2012
  • Report of a consensus conference on transplant program quality and surveillance.  12:1988-1996. 2012
  • The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival.  12:1924-1928. 2012
  • Organ donation and moyamoya disease.  12:1353-1355. 2012
  • A response to child-to-parent donationa-consideration of age and ethnicity.  12:503. 2012
  • Counseling patients for kidney transplantation: Awkward conversations?.  12:273-274. 2012
  • A realistic proposal - Incentives may increase donation - We need trials now!.  12:1957-1958. 2012
  • The PROMISE study: A phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de Novo kidney transplantation.  11:2675-2684. 2011
  • Elevated plasma long pentraxin-3 levels and primary graft dysfunction after lung transplantation for idiopathic pulmonary fibrosis.  11:2517-2522. 2011
  • The impact of pretransplant mechanical ventilation on short- and long-term survival after lung transplantation.  11:2197-2204. 2011
  • Ethnic and gender related differences in the risk of end-stage renal disease after living kidney donation.  11:1650-1655. 2011
  • Elevated plasma Clara cell secretory protein concentration is associated with high-grade primary graft dysfunction.  11:561-567. 2011
  • Living donor nephrectomy: Understanding long-term risk in minority populations.  10:2574-2576. 2010
  • Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access.  10:2154-2160. 2010
  • Inflammation in areas of tubular atrophy in kidney allograft biopsies: A potent predictor of allograft failure.  10:2066-2073. 2010
  • Recipient tissue factor expression is associated with consumptive coagulopathy in pig-to-primate kidney xenotransplantation.  10:1556-1568. 2010
  • Access and outcomes among minority transplant patients, 1999-2008, with a focus on determinants of kidney graft survival: Special feature.  10:1090-1107. 2010
  • Investigation of lymphocyte depletion and repopulation using alemtuzumab (Campath-1H) in cynomolgus monkeys.  10:773-783. 2010
  • Proinflammatory events and HLA antibodies..  10:956. 2010
  • Editorial: Allograft fibrosis - Unmasking the players at the dance.  10:201-202. 2010
  • Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: Preliminary data from the DeKAF study.  10:315-323. 2010
  • Impact of thrombocytopenia on survival of baboons with genetically modified pig liver transplants.  10:273-285. 2010
  • Pathological and clinical characterization of the 'Troubled transplant': Data from the DeKAF study.  10:324-330. 2010
  • Candida in solid organ transplant recipients.  9. 2009
  • Impact of medicare coverage on disparities in access to simultaneous pancreas and kidney transplantation.  9:2785-2791. 2009
  • Long-term controlled normoglycemia in diabetic non-human primates after transplantation with hCD46 transgenic porcine islets.  9:2716-2726. 2009
  • Endoscopic gastric submucosal transplantation of islets (ENDO-STI): Technique and initial results in diabetic pigs.  9:2485-2496. 2009
  • Long-term management of the liver transplant patient: Recommendations for the primary care doctor: Special feature.  9:1988-2003. 2009
  • Use of cardioprotective medications in kidney transplant recipients.  9:1811-1815. 2009
  • Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: The opticept trial.  9:1607-1619. 2009
  • Secondary listing for deceased-donor kidney transplantation does not increase likelihood of engraftment at a large transplant center: Brief communication.  9:1671-1673. 2009
  • Transplant tourism and unregulated black-market trafficking of organs.  9:1484. 2009
  • Isolated central nervous system posttransplant lymphoproliferative disorder treated with high-dose intravenous methotrexate.  9:1243-1248. 2009
  • Renal and cardiac endothelial heterogeneity impact acute vascular rejection in pig-to-baboon xenotransplantation.  9:1006-1016. 2009
  • Plasma cytokines and chemokines in primary graft dysfunction post-lung transplantation.  9:389-396. 2009
  • Cardiac allograft remodeling after heart transplantation is associated with increased graft vasculopathy and mortality.  9:132-139. 2009
  • Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody.  9:2136-2139. 2009
  • The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection.  9:231-235. 2009
  • Rejection of cardiac xenografts transplanted from α1,3- galactosyltransferase gene-knockout (GalT-KO) pigs to baboons.  8:2516-2526. 2008
  • Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: Preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics.  8:1711-1718. 2008
  • Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients.  8:1297-1302. 2008
  • Effect modification in liver allografts with prolonged cold ischemic time.  8:658-666. 2008
  • Monocyte infiltration and kidney allograft dysfunction during acute rejection.  8:600-607. 2008
  • Expression of complement regulatory proteins in accommodated xenografts induced by anti-α-Gal IgG1 in a rat-to-mouse model.  8:32-40. 2008
  • Plasma intercellular adhesion molecule-1 and von Willebrand factor in primary graft dysfunction after lung transplantation.  7:2573-2578. 2007
  • Outcomes of kidneys from donors after cardiac death: Implications for allocation and preservation.  7:1797-1807. 2007
  • Adeno-associated viral vector-mediated interleukin-10 prolongs allograft survival in a rat kidney transplantation model.  7:1112-1120. 2007
  • Must all living donor compensation be viewed as valuable consideration? [2].  7:1309-1310. 2007
  • The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection.  7:842-846. 2007
  • Cold ischemia time and allograft outcomes in live donor renal transplantation: Is live donor organ transport feasible?.  7:99-107. 2007
  • Limiting financial disincentives in live organ donation: A rational solution to the kidney shortage.  6:2548-2555. 2006
  • Connective tissue growth factor is a biomarker and mediator of kidney allograft fibrosis.  6:2292-2306. 2006
  • The conspicuous costs of more of the same.  6:1503-1504. 2006
  • Islet xenotransplantation: Are we really ready for clinical trials?.  6:1269-1274. 2006
  • Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab [1].  6:1084-1085. 2006
  • Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: Reanalysis of the multicenter trial.  6:993-997. 2006
  • Therapeutic targets in the treatment of allograft fibrosis.  6:867-875. 2006
  • Successful renal transplantation in patients with chronic granulomatous disease.  6:636-639. 2006
  • Invasive fungal infections in low-risk liver transplant recipients: A multi-center prospective observational study.  6:386-391. 2006
  • Everolimus versus azathioprine in maintenance lung transplant recipients: An international, randomized, double-blind clinical trial.  6:169-177. 2006
  • Acute Graft versus host disease after liver transplantation: Patterns of lymphocyte chimerism.  5:2968-2973. 2005
  • Molecular evaluation of BK polyomavirus nephropathy.  5:2883-2893. 2005
  • Understanding the influence of ethnicity on renal allograft survival.  5:2603-2604. 2005
  • Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts.  5:2248-2252. 2005
  • Kidneys from deceased donors: Maximizing the value of a scarce resource.  5:1725-1730. 2005
  • Long-term deterioration of kidney allograft function.  5:1405-1414. 2005
  • Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft function.  5:1011-1020. 2005
  • Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: The Israel Penn International Transplant Tumor Registry experience.  5:775-780. 2005
  • Thoracic organ transplantation in the United States, 1994-2003.  5:934-949. 2005
  • Thoracic organ transplantation in the United States, 1994-2003..  5:934-949. 2005
  • Functionally significant renal allograft rejection is defined by transcriptional criteria.  5:573-581. 2005
  • Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion.  5:465-474. 2005
  • African-American renal transplant recipients benefit from early corticosteroid withdrawal under modern immunosuppression.  5:356-365. 2005
  • Evidence for cooperativity in the rejection of cardiac grafts mediated by CD4+ TCR Tg T cells specific for a defined allopeptide.  4:1762-1768. 2004
  • Calcium oxalate deposition in renal allografts: Morphologic spectrum and clinical implications.  4:1338-1344. 2004
  • Successful Renal Transplantation in a Patient with Congenital Generalized Lipodystrophy: A Case Report.  4:447-449. 2004
  • Suppression of Natural and Elicited Antibodies in Pig-to-Baboon Heart Transplantation Using a Human Anti-Human CD154 mAb-Based Regimen.  4:363-372. 2004
  • Whither Living Donors?.  4:2-3. 2004
  • Correlation of Biochemical and Hematological Changes with Graft Failure Following Pig Heart and Kidney Transplantation in Baboons.  3:1510-1519. 2003
  • Equivalent Pharmacokinetics of Mycophenolate Mofetil in African-American and Caucasian Male and Female Stable Renal Allograft Recipients.  3:1581-1586. 2003
  • Reduced efficacy of ganciclovir against porcine and baboon cytomegalovirus in pig-to-baboon xenotransplantation.  3:1057-1064. 2003
  • Inhibition of prolyl-4-hydroxylase ameliorates chronic rejection of mouse kidney allografts.  3:396-402. 2003
  • Porcine antigen presenting cells produce soluble adjuvants that stimulate B cells within and across the species.  3:403-415. 2003
  • Relative perioperative bradycardia does not lead to adverse outcomes after cardiac transplantation.  3:484-491. 2003
  • Stable α- and β-islet cell function after tolerance induction to pancreatic islet allografts in diabetic primates.  3:128-138. 2003
  • Determinants of cardiovascular mortality after renal transplantation: A role for cytomegalovirus?.  3:79-81. 2003
  • Diabetes mellitus after kidney transplantation.  3:512-513. 2003
  • Pretransplant MELD score as a predictor of outcome after liver transplantation for chronic hepatitis C.  3:626-630. 2003
  • The report of a national conference on the wait list for kidney transplantation.  3:775-785. 2003
  • Hand-assisted laparoscopic living-donor nephrectomy as an alternative to traditional laparoscopic living-donor nephrectomy.  2:983-988. 2002
  • Use of preserved vascular homografts in liver transplantation: Hepatic artery aneurysms and other complications.  2:471-475. 2002
  • Genetically modified adenovirus vector containing an RGD peptide in the HI loop of the fiber knob improves gene transfer to nonhuman primate isolated pancreatic islets.  2:237-243. 2002
  • The general public's concerns about clinical risk in live kidney donation.  2:186-193. 2002
  • Addressing minority issues in renal transplantation: Is more equitable access an achievable goal?.  2:1-3. 2002
  • CTLA-4lg in combination with anti-CD40L prolongs xenograft survival and inhibits anti-Gal Ab production in GT-Ko mice.  2:41-47. 2002
  • Fatal Disseminated Aspergillosis following Sequential Heart and Stem Cell Transplantation for Systemic Amyloidosis.  1:93-95. 2001